Our partners

Our partners' expertise and engagement are fundamental to driving long-term and measurable changes in cancer control.
a woman and a man shaking hands at 2019 World Cancer Leaders Summit in Kazakhstan

Click on the logos here below to see more information about each partner.

If you would like to learn more about partnering with UICC, please contact our Partnerships Team at partnerships@uicc.org

Find out more about the Clean Air Fund.

Visit their website

Expertise France works on cancer control through several tobacco control projects, a pediatric cancer project and a palliative care project in LMICs. NCD is a key area of work for Expertise France and we aim to enhance our work on cancer control.

An umbrella foundation associated with the bank Lombard Odier and a registered charity, Fondation Philanthropia has been helping its donors bring their philanthropic initiatives to fruition in all areas of social responsibility since 2008. It provides philanthropic expertise and support to those who wish to develop a philanthropic project in line with their background, desires and ambitions. The Foundation offers its donors a legal, financial and philanthropic framework for made-to-measure projects.

The Foundation now operates more than 20 personal funds and has received over 115 million Swiss francs in donations, of which over a third has already been distributed or committed. Its donors have been highly committed to the fight against cancer, with over 15 million spent on the cause.

Gates Foundation's mission is to create a world where every person has the opportunity to live a healthy, productive life.

Visit their website

Global Equity partners

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.  

Bristol-Myers Squibb is a global BioPharma company firmly focused on its mission to discover, develop and deliver innovative medicines to patients with serious diseases.

Cancer Research UK is the world’s largest independent funder of cancer research. Its vision is to bring forward the day when all cancers are cured. Since 1902 CRUK has found new ways to prevent, diagnose and treat cancer. CRUK-funded scientists’ pioneered early radiotherapy, developed some of the world’s top cancer drugs and discovered the tumour suppressor gene, p53. Its work has saved millions of lives across the world. CRUK invests $500m annually in world-leading research across all 200 different types of cancer, working with partners in Europe, North America and Asia to accelerate research progress. It provides information to those affected by cancer, works to increase cancer awareness, and uses its powerful, independent voice to keep cancer at the top of the political agenda. CRUK funds some of the world’s leading experts in tobacco research and is a key player in international tobacco control. It became a full UICC member in 1986.

Founded in 1951 to support cancer research, the Swedish Cancer Society is an independent non-profit organization with the vision of finding cures for cancer. The overall aim of the Society is to achieve a higher survival rate and a reduction in the incidence of cancer. Their main task is to raise and distribute money for cancer research. As one of the largest financiers of cancer research in Sweden, the Swedish Cancer Society essentially acts as a national research council. Thanks to the organization’s extensive knowledge about cancer, the Swedish Cancer Society is also active in areas such as public opinion and spreading knowledge about cancer, as well as results of cancer research.

The Dutch Cancer Society is a nation-wide organization for cancer control in the Netherlands. The society was funded in 1949 by Queen Wilhelmina. Her granddaughter, Her Royal Highness Princess Beatrix, is the current patron. The Dutch Cancer Society’s ideal world is one in which nobody dies from cancer ever again. We want fewer people to get cancer, more people to cure, and patients to have a better quality of life, during and after the disease. That’s why we fund and facilitate scientific research, influence policy, and share our knowledge about cancer and its treatment. To make this possible, we raise funds and establish links with other parties involved in cancer control, both here in the Netherlands and elsewhere. The Dutch Cancer Society is entirely dependent on community involvement and donations. Over 100.000 volunteers support the Dutch Cancer Society whether it comes to local or nation-wide fundraising, scientific or policy advice in several councils and committees. We can rely on nearly 1.500 local committees that organize fundraising activities e.g. our annual door-to-door campaign to raise funds for the fight against cancer. The Dutch Cancer Society is supported by over 1 million donors. The Dutch Cancer Society’s office is located in Amsterdam; our professional staff amounts to 198 staff members.

For more than a century, MSD, a leading global biopharmaceutical company, has been inventing for life, bring forward medicines and vaccines for the world’s most challenging diseases.  MSD is a trade name of Merck & Co., Inc., Kenilworth, N.J., USA. Through their prescription medicines, vaccines, biologic therapies, and animal health products, they work with customers and operate in more than 140 countries to deliver innovative health solutions. MSD also demonstrates their commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases including HIV and Ebola.

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development and manufacture of healthcare products. Our global portfolio includes medicines and vaccines, as well as many of the world’s best-known consumer healthcare products. We work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. We collaborate with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims for improving patient access to medical innovations by working with all relevant stakeholders. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines.

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2016 employed more than 94,000 people worldwide.

Vanguard partners

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan. They provide innovative products and services in more than 20 countries around the world. With more than 100 years of scientific expertise, their company draws upon a rich legacy of innovation and a robust pipeline of promising new medicines to help patients.

Through the outstanding knowledge and commitment of their 15,000 employees worldwide, they create innovative new and generic medicines, and new methods of drug discovery and delivery. Daiichi Sankyo share a passion for innovation, as well as compassion for the patients around the world who are in need of their medicines.

N°1 dermatologist recommended skincare brand worldwide, La Roche-Posay’s mission is to offer life-changing dermatological skincare solutions. 
The La Roche-Posay Cancer Support program includes two pillars related to the fight against cancer: Fight With Care to improve patients’ quality of life during all cancer treatment for better adherence and higher chances of healing, and Save Your Skin to prevent skin cancer. On both topics, the brand is committed to raising awareness, training health care professional and the general public, and helping patients by supporting NGOs’ projects beyond skincare.
Recommended by 90,000 dermatologists worldwide, La Roche-Posay was created by a pharmacist in 1975 and is now present in over 60 countries. It offers a unique range of daily skincare developed for every skin type to complement their dermatological treatments and promote good skincare practices adapted to each skin concern. The brand develops formulas with its exclusive Selenium-rich water with antioxidant and soothing properties, also used at its Thermal Center, the first Dermatology Center in Europe. The products are developed using a strict formulation charter with a minimal number of ingredients and are formulated at optimal concentrations. Additionally, La Roche-Posay products undergo stringent clinical testing for efficacy and safety, even on sensitive skin.  

The National Cancer Institute (NCI) is the federal government's principal agency for cancer research and training. The NCI coordinates the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients.

Novartis Oncology is a global leader in transforming outcomes for people with cancer. We offer a wide range of innovative therapies to help meet patient needs and have one of the strongest, most productive pipelines in the industry. Our research is driven by a distinctive scientific and clinical strategy focused on precision oncology – understanding how cancer develops on a genomic level and developing drugs that hone in on those targets.

Benefactor partners

AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries.

Bayer is a Life Science company with a more than 150-year history and core competencies in the areas of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen.

The Canadian Partnership Against Cancer is an independent organisation funded by the federal government to accelerate action on cancer control for all Canadians. The Partnership works with cancer experts, charitable organisations, governments, cancer agencies, national health organisations, patients, survivors and others to achieve their shared goal of a future in which fewer Canadians get cancer, fewer die from it and those living with the disease have a better quality of life. The Partnership’s work spans the cancer control continuum, from prevention and screening to research and supportive care. Their collaborative approach is mindful of the patient voice, and strives to be culturally responsive to the needs of local communities.

Danish Cancer Society aims to prevent the development of cancer, to improve patients' chances of successful recovery, to limit the physical, psychological and social side-effects of cancer.

The group`s main activities are within research, patient support and prevention. The society has recently begun to focus on wellness programs like: health, food, and biotech advances.

Hologic, Inc. is a global medical technology innovator primarily focused on improving women’s health and well-being through early detection and treatment. Its advancements include leadership in providing diagnostic solutions for cervical cancer screening, sexually transmitted infections, respiratory illnesses, and the virus that causes COVID-19; invention of the world’s first commercial 3D mammography system to fight breast cancer; and minimally invasive surgical technologies for uterine fibroids and abnormal uterine bleeding. The company champions women through the Hologic Global Women’s Health Index, which provides a science-backed data roadmap for improving women’s well-being, and Project Health Equality, which elevates awareness, research insights and access to quality care for underserved women.

The mission of The University of Texas MD Anderson Cancer Center is to eliminate cancer in Texas, the nation, and the world through outstanding programs that integrate patient care, research and prevention, and through education for undergraduate and graduate students, trainees, professionals, employees and the public.

National Cancer Centre (NCC) was established in 2000. It strives to improve national health and welfare by reducing the incidence and mortality of cancer through research, patient care, education & training, and support for the national cancer control programs. "Vision 2020" is a program that represents the organizations goals into the future, where it fights to protect the Korean people from cancer through innovative research, quality medical care, optimal training of cancer experts, and support for national cancer control programs. 

The mission of the Prevent Cancer Foundation® is saving lives across all populations through cancer prevention and early detection. The Prevent Cancer Foundation® is one of the leading voluntary health organizations in the U.S. and the only U.S. non-profit focused solely on cancer prevention and early detection. Founded in 1985, it has catapulted cancer prevention to prominence and fulfils its mission through research, education, outreach and advocacy. The Foundation’s vision is to Stop Cancer Before It Starts!®

Servier Group is dedicated to advancing therapeutic progress to meet patient needs. The organisation values its independence, which allows it to make strategic decisions and adopt a long-term vision. This independence supports its mission to serve patient needs through therapeutic advancements. The focus is on addressing the needs of patients and healthcare professionals, collaborating closely on innovative solutions while considering the impact on society and the environment. The research efforts are concentrated on cardiovascular diseases, cancers, diabetes, immune-inflammatory, and neuropsychiatric diseases.

The Japan National Committee for UICC is a group of Japanese organisations that are members of the Union for International Cancer Control (UICC), gathered to support the UICC to strive to realise the World Cancer Declaration. Currently UICC-Japan is composed of 29 full Japanese UICC members, including major cancer specialists in Japan, cancer centres, research institutes, research funds, hospitals and cancer associations.

Wiley is a global provider of content and content-enabled workflow solutions in areas of scientific, technical, medical, and scholarly research; professional development; and education. Their core businesses produce scientific, technical, medical, and scholarly journals, reference works, books, database services, and advertising; professional books, subscription products, certification and training services and online applications; and education content and services including integrated online teaching and learning resources for undergraduate and graduate students and lifelong learners.

 

World Cancer Research Fund International (WCRF International) leads and unifies a global network of cancer charities dedicated to the prevention and control of cancer by means of healthy food and nutrition, physical activity and weight management. In particular, WCRF International plays a leading role in directing and supporting the research activities of the WCRF global network. Working with researchers, health professionals, policy makers and other health organisations throughout the world, we provide people with the information they need to make choices that can reduce their chances of developing cancer. WCRF's vision is that the their global network helps people make choices that reduce their chances of developing cancer. They were the first cancer charity to create awareness of the relationship between diet and cancer risk, to focus funding on research into diet and cancer prevention and to consolidate and interpret global research to create a practical message on cancer prevention.

Champion partners

BeiGene is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. With a broad portfolio of more than 40 clinical candidates, BeiGene is expediting development of our diverse pipeline of novel therapeutics through our own capabilities and collaborations. We are committed to radically improving access to medicines for two billion more people by 2030.

The McKinsey Cancer Center (McKCC) combines the extensive cross-functional oncology experience of our team with methodologies for generating deep market insights, advanced-analytics platforms, and input from a network of leading external experts. We work to advance cutting-edge oncology innovations (both therapeutic and diagnostic) with pharmaceutical and biotech companies and investors. Approaches we design make it possible for health-care providers to deliver better care, and solutions we propose help health systems and policy makers realize the best possible outcomes for cancer patients. Operating in all geographies, the McKinsey Cancer Center conducts more than 100 client engagements annually across strategy, R&D, business development, marketing and sales, market access and policy, and care-delivery topics. We share our cutting-edge knowledge at international oncology conferences, as well as in peer-reviewed publications and other leading industry journals.

High quality therapeutics and diagnostics solutions for patients, ethics as our underlying principle, dedication to innovation and advancement, strong people centricity and environmental sustainability. These five pillars form the foundation of the Menarini Group, an Italian pharmaceutical company with more than 135 years of history. Founded in 1886 in Naples under the name of Farmacia Internazionale, in 1915 Menarini moved to Florence where the Group’s headquarters are still located today. The Menarini Group is present in 140 countries around the world. Its companies span from Europe to Asia, to Africa and the Middle East, to Central America and to the United States where with the acquisition of Stemline Therapeutics, a NASDAQ-listed biopharmaceutical company, the company marked its entry into the US oncology market.

Visit their website

NCS is an active civil society actor which contributes to targeted efforts in cancer information, prevention, advocacy, research, care, and international cooperation. Their activities are funded thanks to the contributions of its members, bequests, and allocations from the national lottery funds. Their main objectives are to: Contribute to ensure that fewer people develop cancer (reduction of the prevalence and incidence of cancer), Contribute to more people surviving cancer, Ensure the best quality of life for people affected by cancer (cancer patients and their relatives). The vision of NCS is: “Together we create hope”.

The world-leading journal dedicated to clinical oncology research

The Lancet Oncology covers topics that advance clinical practice, challenge the status quo, advocate change in health policy, and tackle issues related to global oncology. Topics include but are not limited to breast cancer; endocrine system cancer; gastrointestinal cancer; genitourinary cancer; gynaecological cancer; haematological cancer; head and neck cancer; neurooncology; paediatric oncology; thoracic oncology; sarcoma; skin cancer; epidemiology, cancer prevention, and cancer control; supportive care; imaging; and health-care systems.

We have also fostered a reputation for hosting events for oncologists, cancer researchers, and policymakers, and convenes many conferences, either independently or in collaboration with partners. Events include branded plenary lectures and sessions at conferences worldwide: Asian Oncology Summit, The Lancet Summit: Cancer care in Asia and Latin America, Oncology At The Limits, Frontiers of Oncology, and Advancing Cancer Immunotherapy, to name just a few.

We publish a range of article types that encompass all aspects of oncological medicine: Articles, Review, Policy Review, Personal View, Clinical Picture, Comment, Correspondence, News, and Perspectives. We also publish Series and Commissions (typically in partnership with societies, governments, NGOs, and academic centres) that aim to shape and drive positive change in clinical practice and health policy in areas of need in global oncology. Learn more about the types of papers we publish.

Supporters

Love, Hope, Strength Foundation · 
Two men shaking hands and smiling

UICC has a long history of uniting with partners to reduce the global cancer burden.

Partners
Speakers at 2012 World Cancer Congress Montreal

Becoming a UICC partner is a valuable opportunity for an organisation to expand its global impact on cancer control and to address Sustainable Development Goal 3, to “ensure healthy lives and promote well-being for all at all ages”.

Become a partner
Two people at a UICC event

UICC is grateful for the support of all its partners and their dedication to UICC’s mission and programmatic areas. Here you will find the latest updates on UICC partnerships. ​

UICC partner updates
Tags Partners Partnership

Last update

Tuesday 04 March 2025

Share this page